UBS lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $22 from $25 and keeps a Buy rating on the shares. Acadia reported Q1 Nuplazid results above consensus, while Daybue results were below estimates, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target lowered to $18 from $19 at BofA
- ACADIA Pharmaceuticals: Promising Growth Potential and Strategic Stability Reinforce Buy Rating
- Insider Moves: ACADIA, EPR, Apple, Kratos, Energy Fuels
- Acadia Pharmaceuticals assumed with an Equal Weight at Morgan Stanley
- Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects